Introduction
De-orphaning of G-protein coupled receptor GPR40 in 2003 led to its being re-named as free fatty acid receptor 1 (FFA1) due to the demonstrated involvement of medium-to long-chain endogenous fatty acids in its activation [1] . Shortly thereafter, it was shown that the endogenous ligand binding to FFA1 regulates the secretion of insulin in pancreatic β-cells and is, therefore, linked to glucose homeostasis. Interestingly, the basal expression levels of FFA1 in normal state are low but do become upregulated in hyperglycemic states, which makes the receptor an ideal target for therapeutic intervention. Moreover, once the glucose levels are normalized, the level of FFA1 expression goes back to normal thereby preventing hypoglycemia, even if an agonist is still in circulation [2] . Taken together, these observations unquestionably validated FFA1 as a therapeutic target of great promise in delivering new treatment for type 2 diabetes mellitus (T2DM) which would be devoid of adverse reactions of the drugs currently in clinical use. The interest toward this target from the industry and academic research teams was clearly evidenced by the discovery of a number of synthetic agonists over the decade following FFA1 validation as an antidiabetic target [3] . Unfortunately, the field was adversely affected by the discontinuation of the phase III clinical trials of Takeda's fasiglifam in December 2013 due to idiosynchratic liver toxicity observed within an extended patient population, which caused a sharp drop in the amount of effort worldwide to bring new FFA1 agonists as drugs to the market [4] . At the time of preparing this manuscript, only two phase I clinical studies (Piramal's compound P11187 of undisclosed structure and SHR0534 or fusiglifam from Hengrui) were underway [5] . This is rather unfortunate as in fact, the proof of principle for the new therapeutic approach was clearly obtained in the course of TAK-875 clinical research [6] . Considering the fact that FFA1 is mainly expressed in the pancreas and in the brain [7] , the hepatotoxicity of TAK-875 is likely related to the specific molecular structure of this (rather lipophilic [8] ) molecule and not to the action at the receptor. In fact, much of the research in the last 3 years (i. e. after the discontinuation of TAK-875) has been focused on the discovery and development of more polar, less lipophilic FFA1 agonists [9] . typically includes fine-tuning of either the polar appendage groups around the 3-phenypropionic acid pharmacophore (as in, for example, 1 [11] and 2 [12] ) or replacing this core with more polar heterocyclic congeners, i.e. applying the scaffold-hopping approach exemplified by 3 [13] and 4
[14] (Figure 1 ). Ideally, this is done in conjunction with attempts to create new specific interactions with the target that could compensate for the affinity loss due to the decreased lipophilicity [12, 14] . Recently, we became intrigued by the structure of LY2881835 (5), Eli Lilly's advanced FFA1 agonist, which progressed through phase I clinical trials [3] . In addition to 3-phenylpropanoic acid pharmacophoric core, the compound contains a spirocyclic piperidine moiety with a basic amine nitrogen atom, which constitutes an unusual feature for the FFA1 agonist landscape [4] . More importantly, it extends the range of structural motifs that can be explored as periphery 'decoration' of potential FFA1 agonists in the ongoing quest for more polar compounds (as the tertiary amine nitrogen will most likely be protonated at physiological pH). In this context, we saw a great opportunity to incorporate a greater diversity of spirocyclic motifs (amenable by our recently reported Prins cyclization protocol [15] ) into a new series of FFA1 agonists inspired by LY2881835. Spirocyclic moieties in general are considered privileged structures for GPCR ligand design due to their pronounced three-dimensional character, better complementarity to the protein target of interest and lower off-target effects [16] . This prompted us to develop a series of spirocyclic compounds which delivered lead structure 6 [17] . It has a potency of 55 nM which is in sharp contrast with inactive compound 7 where the 1-oxa-9-azaspiro [5.5] undecane periphery is unsubstituted. More recently, we have also demonstrated that incorporation of significantly more polar isosteres (as in compound 8, which is somewhat less potent with an EC50 900 nM) was also possible and is not detrimental to compound's potency [18] . For compound 6, we demonstrated that the presence of the benzyl substituent (which is absent in inactive compound 7) provides more than just a lipophilicity-driven potency increase. The benzyl group appeared to define a specific orientation of the spirocyclic moiety in 6 (pointing toward the intracellular side of the receptor) reinforced by a network of favorable hydrophobic interactions with L542.51, L1354.54 and V813.27
as well as a π-stacking interaction with W1314.50 [17] . Such a consideration prompted us to investigate a series of compounds 9 in which a polar heteroaromatic moiety (as that in compound 8) would be attached to the crucial 1-oxa-9-azaspiro[5.5]undecane system via a more flexible, 3atom linker to enable the compound to assume a more energetically favored conformation and accommodate the azine periphery within the nearby binding pocket ( Figure 2 ). Herein, we disclose our recent results in this regard.
Results and discussion

Chemistry
Retrosynthetically, the target compounds could be disconnected to building blocks 10 and 13, gram-scale synthesis of which had been reported earlier [17, 19] (Figure 3 ). This synthetic strategy was realized as shown in Scheme 1. Key spirocyclic ketone 13 was prepared on multigram scale via the Prins cyclization of 1-benzyl-4-piperidone and homoallyl alcohol followed by the protecting group exchange [15] and secondary alcohol oxidation with PDC [17] . The subsequent 2-hydroxyethyl side chain installation was achieved in three chemical operations including the Horner-Wadsworth-Emmons olefination reaction, double bond hydrogenation over a palladium catalyst using ammonium formate as a hydrogen source, and the LAH reduction of the ester functionality to the respective primary alcohol 12. A reasonable total chemical yield of 41% was achieved for the three synthetic steps. Having installed the requisite 2-hydroxyethyl side chain, we proceeded to decorate it with a range of (hetero)aromatic groups. Most of these could be installed via a direct SNAr-type reaction of the alkoxide generated from 12 with heteroaromatics containing labile chloro-substituent. Alternatively, respective hydroxyaromatic building block was coupled to 12 under the standard Mitsunobu conditions. Removal of the Boc protecting group with TFA furnished spirocyclic piperidine building blocks 11a-m which were alkylated with aldehyde 10 in reductive conditions (STAB) and, without purification, the resulting tert-butyl ester precursors were converted, using 4M HCl in 1.4-dioxane, to free carboxylic acids 9a-m, which were isolated as hydrochloride salts (Scheme 1).
Biological activity
Potential FFA1 agonists 9a-m synthesized as described above, were tested for their ability to activate FFA1 using calcium flux assay employing Chinese hamster ovary (CHO) cells engineered to stably express human FFA1. All compounds were tested in dose-response mode in order to calculate the respective EC50 values and determine % of maximum efficacy achieved for active compounds relative to commercially available reference FFA1 agonist GW9508 [20] .
From the data obtained on activation of FFA1 receptor by compounds 9a-m (Table 1) , it becomes evident that the idea of presenting polar aromatic periphery on an extended, three-atom linker resulted in low-micromolar potency for the majority of compounds (while the low potency of 9b is somewhat puzzling). Starting from the best compound in the azine-decorated series (8, EC50 = 0.9 µM, vide supra) we reported earlier [18] , the goal in present study was to optimize the same or similar polar azine (or other aromatic) periphery to be accommodated in the nearby binding pocket. The bioactivity data in Table 1 essentially reflect the gradual fine-tuning of the potency and the efficacy of compounds 9a-m until the best fit to the binding pocket manifests itself in compound 9i, which we regard as unquestionable frontrunner in this series. Compound 9i not only displays a pronounced restoration of the receptor affinity by the side chain present in it compared to its unsubstituted (inactive) counterpart 7, it also shows a significant improvement over its double homolog 8. Considering the fact that compounds 9h and 9i are mere positional isomers and, therefore, have an identical cLogP of 5.84 [21] , the >4-fold difference in potency is likely attributable to the better accommodation of 9i by FFA1 (vide infra). We further profiled lead compound 9i for selectivity against other free fatty acid receptors (FFA3/GPR41, FFA2/GPR43 and FFA4/GPR120). FFA2 and FFA3 bind short-chain fatty acids preferentially, while FFA1 and FFA4 have a higher affinity to medium-and long chain fatty acids [22] [23] . Compound 9i showed no activation of any of these receptors (except for FFA1) at concentrations as high as 10 µM (Table 2) . We also obtained the preliminary ADME profile of 9i by determining its Caco-1 permeability, stability toward incubation with mouse liver microsomes (MLM) and solubility in aqueous phosphate buffer solution (Table 3) . Unsurprisingly, the polar substituted pyridine periphery led to significant aqueous solubility and the compound had a good Caco-2 permeability. The metabolic stability was somewhat low which was already reported for compounds with a similar molecular scaffold [17] . The rapid MLM clearance can indeed be attributed to the presence of two heteroatom-substituted benzylic positions in 9i and/or β-unsubstituted which is a known weak spot of FFA1 agonists, prone to metabolic oxidation [4] . 
a Each value is an average of n = 4, measured at c = 1 µM. b Each value is an average of n = 2, measured at c = 10 µM.
Docking studies
In order to rationalize the dramatic difference in potency between unsubstituted spirocyclic compound 7 reported earlier [17] and frontrunner compound 9i identified in this study, which differ only in the presence of 2-[(6-methylpyrid-2-yl)oxy]ethyl side chain in the 1-oxa-9-azaspiro[5.5]undecane portion of 9i, we docked these compounds in the FFA1 binding site ( Figure   4 ). Figure   4B ). Apparently, the attachment of the pyridyl moiety to the spirocyclic fragment of 7 with a flexible, three-atom linker allows an optimal positioning of the periphery heterocycle within this cavity with negligible strain on the ligand. It is clearly visible that the 6-methyl substituent is buried within the cavity, which facilitates the formation of the π−π stacking contact between the pyridine ring and W1314.50. The latter appears to be vital for stabilizing the bound conformation of the ligand and its strength depends on the substituents in the aromatic rings involved in the interaction [25] . This observation could, for instance, help rationalize the significantly decreased potency of compound 9b (EC50 = 33.5 µM), which is the only one in the series that has a strongly electron-withdrawing substituent in the azine ring.
Conclusions
We have successfully explored the possibility of decorating the 1-oxa-9-azaspiro[5.5]undecane portion of inactive compound 7 (reported earlier as inspired by LY2881835) with polar (hetero)aromatic heterocycles attached via a flexible 3-atom linker to enable the optimal accommodation of these residues within the hydrophobic pocket identified earlier near the binding site of FFA1 agonists. One of the resulting compounds (9i) displayed a high potency and efficacy as FFA1 agonist and demonstrated excellent aqueous solubility, Caco-2 permeability and somewhat rapid metabolism in the presence of human liver microsomes. The compound clearly provides a strong proof-of-principle for the design approach taken toward new antidiabetic agents acting via FFA1 activation that includes the use of polar periphery residues. These findings significantly expand the FFA1 agonist chemistry space for the ongoing quest for new, more polar agents that would have a lesser chance of displaying idiosyncratic hepatotoxicity.
Experimental protocols
All reactions were conducted in oven-dried glassware in atmosphere of nitrogen. Melting points
were measured with a Buchi В-520 melting point apparatus and were not corrected. Analytical thin-layer chromatography was carried out on Silufol UV-254 silica gel plates using appropriate mixtures of ethyl acetate and hexane. Compounds were visualized with short-wavelength UV light. 1 H NMR and 13 C NMR spectra were recorded on Bruker MSL-300 spectrometers in DMSO-D6-d6 using TMS as an internal standard. Mass spectra were recorded using Shimadzu LCMS-2020 system with electron-spray (ESI) ionization. All and reagents and solvents were obtained from commercial sources and used without purification.
All mass-spectroscopic measurements required for determination of ADME properties were performed using Shimadzu VP HPLC system including vacuum degasser, gradient pumps, reverse phase HPLC column, column oven and autosampler. The HPLC system was coupled with tandem mass spectrometer API 3000 (PE Sciex). The TurboIonSpray ion source was used in both positive and negative ion modes. Acquisition and analysis of the data were performed using Analyst 1.5.2 software (PE Sciex). To a 0 ºC, vigorously stirred suspension of NaH (6.54 g, 163 mmol, 60% dispersion in mineral oil) in THF (300 mL) thriethylphosphonoacetate (45 g, 200 mmol) was added dropwise under argon. The stirring continued at that temperature for 1 h, whereupon a solution of 13 (40 g, 149 mmol), prepared as described earlier [17] , in THF (100 mL) was added. The reaction mixture was allowed to reach r. t. and was stirred at that temperature for 18 h. The reaction mixture was poured into water (500 mL) and the aqueous phase was extracted with ethyl acetate ( was filtered off and the filtrate was concentrated in vacuo. The residue was dissolved in CH2Cl2 (10 mL), the solution was cooled to 0 ºC and TFA (3 mL) was added. The mixture thus obtained was stirred at 0 ºC for 6 h and then concentrated in vacuo to dryness to provide, after crystallization from isopropyl alcohol, the target compounds as ditrifluoroacetate salts. 
Synthesis
4-(2-{[5-(Trifluoromethyl)pyridin-2-yl]oxy}ethyl)-
General procedure 2 (GP2): preparation of 1-oxa-9-azaspiro[5.5]undecanes 11a and 11m
To a 0 ºC solution of 13 (1.0 g, 3.3 mmol), hydroxyaromatic coupling partner (4.3 mmol) and triphenylphosphine (1.29 g, 4.9 mmol) in dry THF (100 mL) a solution of DIAD (1.0 g, 4.9 mmol) in dry THF (10 mL) was added dropwise. The resulting mixture was stirred for 16 h at r.t., poured into water (100 mL) and the resulting slurry extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were dried over anhydrous Na2SO4, filtered and concentrated in vacuo.
The residue was dissolved in 7:3 diethyl ether-hexane mixture (30 mL) and the solution cooled to 5 ºC. The precipitate of triphenylphosphine oxide was filtered off and the filtrate concentrated in vacuo. The residue was fractionated on a short column of silica gel using 0  5% ethyl acetate in hexane as eluent. The fractions containing the Mitsunobu reaction product (according to LC MS analysis) were pooled and the solvent was evaporated. The residue was dissolved in CH2Cl2 (10 mL), the solution was cooled to 0 ºC and TFA (3 mL) was added. The mixture thus obtained was stirred at 0 ºC for 6 h and then concentrated in vacuo to dryness to provide, after crystallization from isopropyl alcohol, the target compounds as mono-(11a) or ditrifluoroacetate (11m) salts. 1.14 4-[2-(4-Fluorophenoxy) ethyl]-1-oxa-9-azaspiro [5.5] [drug]init,d -initial concentration of test compound in the donor well.
4.
Docking studies
The 3D coordinates for GPR40 co-crystalized with TAK-875 was obtained from the Protein Data Bank (PDB ID: 4PHU) [27] and used for subsequent docking procedures. Protein preparation, refinement and docking was performed within Schrodinger's Maestro, version 2016-1 [28] . To prepare FFA1 receptor for docking, hydrogens and missing atoms were added, alternate residue positions were defined and the hydrogen bonding network was further optimized by re-orientating hydroxyls, amides and imidazole rings (of histidine residues) using the Protein Preparation Wizard [29] . For selecting an appropriate docking protocol, TAK-875 was re-docked onto FFA1 and compared to the crystal structure orientation, RMSD < 2.5 Å. The remaining parameters and steps for receptor grid generation, ligand preparation and docking protocols were similar to the methodology of our previous studies [14b , 17] . Here we utilized the MacroModel [30] , LigPrep [31] and GLIDE [32] modules of Schrödinger's Maestro. To allow the comparison of residue positions within the GPCR family, the labels of residues are shown the Ballesteros Weinstein indexing system in subscript [24] .
